RT Journal Article
SR Electronic
T1 Reduced Likelihood of Hospitalization with the JN.1 or HV.1 SARS-CoV-2 Variants Compared to the EG.5 Variant
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.08.24307003
DO 10.1101/2024.05.08.24307003
A1 Levy, Matthew E.
A1 Chilunda, Vanessa
A1 Davis, Richard E.
A1 Heaton, Phillip R.
A1 Pawloski, Pamala A.
A1 Goldman, Jason D.
A1 Schandl, Cynthia A.
A1 McEwen, Lisa M.
A1 Cirulli, Elizabeth T.
A1 Wyman, Dana
A1 Rossi, Andrew Dei
A1 Dai, Hang
A1 Isaksson, Magnus
A1 Washington, Nicole L.
A1 Basler, Tracy
A1 Tsan, Kevin
A1 Nguyen, Jason
A1 Ramirez, Jimmy
A1 Sandoval, Efren
A1 Lee, William
A1 Lu, James
A1 Luo, Shishi
YR 2024
UL http://medrxiv.org/content/early/2024/05/09/2024.05.08.24307003.abstract
AB Within a multi-state viral genomic surveillance program, proportions of SARS-CoV-2 infections attributed to the JN.1 and HV.1 variants, compared to EG.5, were each lower among inpatients versus outpatients (aOR=0.33 [95% CI: 0.20-0.55] and aOR=0.62 [95% CI: 0.44-0.86], respectively). JN.1 and HV.1 variants may be associated with a lower risk of severe illness.Competing Interest StatementMEL, VC, LMM, ETC, DW, ADR, HD, MI, NLW, TB, KT, JN, JR, ES, WL, JL, and SL are employees of Helix, Inc. MEL, MI, and SL report contracted research from Pfizer. MEL, MI, WL, and SL report contracted research from the Centers for Disease Control and Prevention (CDC). MEL reports contracted research and travel support from Novavax. PRH reports contracted research from Seegene USA and Helix, Inc. JDG reports contracted research from Helix, Gilead, Eli Lilly, and Regeneron; grants from Merck (BARDA) and Gilead; speaking honoraria and personal fees from Gilead Sciences, Inc, and Eli Lilly & Co; and collaborative services agreements with Adaptive Biotechnologies, Monogram Biosciences, and LabCorp; and serving as a speaker or advisory board member for Gilead and Eli Lilly. CAS reports giving educational lectures sponsored by Eli Lilly. RED and PAP report no potential conflicts.Funding StatementThis study was funded by Helix.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Protocols were reviewed and approved by the WIRB CG IRB (Western Institutional Review Board, WIRB-Copernicus Group; approval number 20224919) and the Medical University of South Carolina (MUSC) Institutional Review Board for Human Research (approval number Pro00129083).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData collected for this study are not available. Data sharing agreements between Helix and partner institutions prohibit Helix from making this dataset publicly available.